{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:53:11Z","timestamp":1740142391967,"version":"3.37.3"},"reference-count":8,"publisher":"FapUNIFESP (SciELO)","issue":"4","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  BACKGROUND:  The infection for the hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality through its evolution to liver cirrhosis, end-stage liver complications and hepatocellular carcinoma. Currently, the new drugs for the HCV infection, based on direct antiviral agents, have changed the outcomes in this setting.  OBJECTIVE:  To assess death incidence, during the wait for the treatment with the new drugs, and to analyze which independent variable (age, sex, ascite, HDA, albumin, \u03b1-fetoprotein, platelets and Meld score) had relation with death.  METHODS:  Prospective study with cirrhotic patients by HCV. Inclusion: cirrhotic patients by hepatic biopsy (METAVIR), clinic or image, detectable RNA (HCV). Exclusion: Other stages of hepatic fibrosis and hepatocellular carcinoma. Descriptive statistic in continue variables. Fisher Exact and Kaplan Meier and Cox Regression Analysis to assess the association of variables studied with death. P&lt;0.05.  RESULTS:  A total of 129 patients were included. Of this, 73% were men. Mean age was 57.8\u00b112.1, albumin of 3.5\u00b10.6 mg\/dL, platelets of 123.4\u00b159.6 and Meld score of 10.59\u00b13.56. The time of observation was 11.2\u00b13.26 months, and the number of death 9\/129 (6,9%). The Kaplan-Meier showed association between death with albumin lower than 2.9 (0.0006), MELD score higher than 15 (0.007) and \u03b1-fetoprotein higher than 40 ng\/mL (&lt;0.0001). Adjusted Cox Regression Analysis showed that \u03b1-fetoprotein higher than 40 ng\/ml could be considered an independent risk for death.  CONCLUSION:  We conclude that, patients with advanced cirrhosis should be prioritized for treatment with direct antiviral agents.<\/jats:p>","DOI":"10.1590\/s0004-2803.201800000-76","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T13:44:16Z","timestamp":1550238256000},"page":"343-345","source":"Crossref","is-referenced-by-count":2,"title":["WAITING DAAS LIST MORTALITY IMPACT IN HCV CIRRHOTIC PATIENTS"],"prefix":"10.1590","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6129-7045","authenticated-orcid":false,"given":"Giovanni Faria","family":"SILVA","sequence":"first","affiliation":[{"name":"Universidade Estadual Paulista,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa Gutierrez de","family":"ANDRADE","sequence":"additional","affiliation":[{"name":"Universidade Estadual Paulista,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alecsandro","family":"MOREIRA","sequence":"additional","affiliation":[{"name":"Universidade Estadual Paulista,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2018,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.gastro.2010.05.017","article-title":"Chronic disease management for patients with cirrhosis","volume":"139","author":"Volk ML","year":"2010","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.3748\/wjg.v20.i29.9633","article-title":"Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy","volume":"20","author":"Ansaldi F","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","article-title":"Liver cirrhosis","volume":"383","author":"Tsochatzis EA","year":"2014","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bjid.2013.05.007","article-title":"Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study","volume":"18","author":"Silva GF","year":"2014","journal-title":"Braz J Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jhep.2006.08.020","article-title":"Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study","volume":"46","author":"Iacobellis A","year":"2007","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D\u2019Amico G","year":"2006","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1053\/j.gastro.2010.06.019","article-title":"Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis","volume":"139","author":"Arvaniti V","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/jvh.12646","article-title":"Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era","volume":"24","author":"McDonald SA","year":"2017","journal-title":"J Viral Hepat"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v55n4\/1678-4219-ag-55-04-343.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T13:37:51Z","timestamp":1579873071000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032018002400343&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":8,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["S0004-28032018002400343"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.201800000-76","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"type":"electronic","value":"1678-4219"},{"type":"print","value":"0004-2803"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}